{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.2","upperLimit":"73.0","value":"59.2"},{"groupId":"OG001","lowerLimit":"39.5","upperLimit":"67.8","value":"53.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants for whom the best overall response was a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as determined by the IMWG-URC.\n\nCR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \\< 5% plasma cells in bone marrow (BM). sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \\< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \\< 200 mg/24-hours.\n\nThe ORR 95% CIs were estimated using the Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory multiple myeloma received a triplet combination of KRd.\n\nCarfilzomib was administered as a 10-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day treatment cycles. The starting dose of carfilzomib was 20 mg/m\\^2 on Days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m\\^2 starting on Day 8 of cycle 1 and thereafter. From cycle 13, the Day 8 and Day 9 doses of carfilzomib were omitted. After cycle 18, carfilzomib was discontinued.\n\nLenalidomide 25 mg was taken orally on Days 1 to 21 and dexamethasone 40 mg by mouth or IV infusion on Days 1, 8, 15, and 22 of repeated 28-day treatment cycles.","id":"OG000","title":"Carfilzomib, Lenalidomide and Dexamethasone (KRd)"},{"description":"Participants with relapsed or refractory multiple myeloma received a doublet combination of Kd.\n\nCarfilzomib was administered as a 30-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day treatment cycles. The starting dose of carfilzomib was 20 mg/m\\^2 on Days 1 and 2, and if tolerated, was escalated to a target dose of 56 mg/m\\^2 starting on Day 8 of cycle 1 and thereafter.\n\nDexamethasone 20 mg was taken by mouth or IV infusion on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle.","id":"OG001","title":"Carfilzomib and Dexamethasone (Kd)"}],"paramType":"NUMBER","populationDescription":"Safety analysis set included all enrolled participants who received at least one dose of IP.","reportingStatus":"POSTED","timeFrame":"From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months","title":"Overall Response Rate (ORR) as Per IMWG-URC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}